Banco Macro Sa (BMA) Stock Price Rose While Ashmore Group Plc Decreased by $1.87 Million Its Position; Amicus Therapeutics (FOLD) Position Maintained by Perceptive Advisors Llc

February 20, 2018 - By Hazel Jackson

Joseph Edelman increased its stake in Amicus Therapeutics Inc (FOLD) by 3.42% based on its latest 2017Q3 regulatory filing with the SEC. Perceptive Advisors Llc bought 591,925 shares as the company’s stock rose 23.92% with the market. The hedge fund run by Joseph Edelman held 17.89 million shares of the health care company at the end of 2017Q3, valued at $269.76 million, up from 17.30M at the end of the previous reported quarter. Perceptive Advisors Llc who had been investing in Amicus Therapeutics Inc for a number of months, seems to be bullish on the $2.87 billion market cap company. The stock increased 1.87% or $0.28 during the last trading session, reaching $15.45. About 693,260 shares traded. Amicus Therapeutics, Inc. (NASDAQ:FOLD) has risen 12.45% since February 20, 2017 and is uptrending. It has underperformed by 4.25% the S&P500.

Ashmore Group Plc decreased its stake in Banco Macro Sa (BMA) by 17.86% based on its latest 2017Q3 regulatory filing with the SEC. Ashmore Group Plc sold 15,975 shares as the company’s stock rose 7.03% with the market. The institutional investor held 73,471 shares of the commercial banks company at the end of 2017Q3, valued at $8.62M, down from 89,446 at the end of the previous reported quarter. Ashmore Group Plc who had been investing in Banco Macro Sa for a number of months, seems to be less bullish one the $8.22B market cap company. The stock increased 0.13% or $0.135 during the last trading session, reaching $108.035. About 48,166 shares traded. Banco Macro S.A. (NYSE:BMA) has risen 43.80% since February 20, 2017 and is uptrending. It has outperformed by 27.10% the S&P500.




Analysts await Banco Macro S.A. (NYSE:BMA) to report earnings on February, 21. They expect $2.69 EPS, up 43.09% or $0.81 from last year’s $1.88 per share. BMA’s profit will be $204.67M for 10.04 P/E if the $2.69 EPS becomes a reality. After $2.24 actual EPS reported by Banco Macro S.A. for the previous quarter, Wall Street now forecasts 20.09% EPS growth.

Among 5 analysts covering Banco Macro SA (NYSE:BMA), 1 have Buy rating, 0 Sell and 4 Hold. Therefore 20% are positive. Banco Macro SA had 7 analyst reports since February 9, 2016 according to SRatingsIntel. The stock has “Neutral” rating by UBS on Wednesday, June 1. Credit Suisse initiated it with “Neutral” rating and $71 target in Tuesday, March 29 report. As per Tuesday, June 13, the company rating was upgraded by Credit Suisse. The stock of Banco Macro S.A. (NYSE:BMA) earned “Hold” rating by Goldman Sachs on Monday, September 11. The stock of Banco Macro S.A. (NYSE:BMA) has “Buy” rating given on Monday, September 26 by Goldman Sachs. The firm has “Neutral” rating given on Monday, May 23 by Citigroup.

Ashmore Group Plc, which manages about $216.65 million US Long portfolio, upped its stake in Ypf Sociedad Anonima (NYSE:YPF) by 65,321 shares to 207,494 shares, valued at $4.62 million in 2017Q3, according to the filing. It also increased its holding in Petroleo Brasileiro Sa Petro by 2.44M shares in the quarter, for a total of 3.43 million shares, and has risen its stake in Fomento Economico Mexicano S (NYSE:FMX).

Since October 12, 2017, it had 0 insider buys, and 16 sales for $11.04 million activity. 10,000 shares were sold by Baird William D III, worth $147,181. 7,000 Amicus Therapeutics, Inc. (NASDAQ:FOLD) shares with value of $99,740 were sold by Quimi Daphne. Barth Jay had sold 20,000 shares worth $336,000 on Tuesday, January 23. $517,371 worth of Amicus Therapeutics, Inc. (NASDAQ:FOLD) was sold by Campbell Bradley L. RAAB MICHAEL had sold 10,000 shares worth $142,534 on Thursday, October 12. Shares for $300,002 were sold by HAYDEN DONALD J JR.

Perceptive Advisors Llc, which manages about $2.09B and $2.62B US Long portfolio, decreased its stake in Acelrx Pharmaceuticals Inc (NASDAQ:ACRX) by 2.49M shares to 1.24M shares, valued at $5.73 million in 2017Q3, according to the filing. It also reduced its holding in Blueprint Medicines Corp by 20,000 shares in the quarter, leaving it with 424,661 shares, and cut its stake in Viveve Medical Inc.

Investors sentiment increased to 2.33 in Q3 2017. Its up 1.10, from 1.23 in 2017Q2. It increased, as 16 investors sold FOLD shares while 32 reduced holdings. 52 funds opened positions while 60 raised stakes. 192.70 million shares or 14.18% more from 168.77 million shares in 2017Q2 were reported. Proshare Advsrs Ltd Liability Corporation invested in 104,050 shares. Gsa Cap Partners Limited Liability Partnership holds 0.02% or 20,506 shares. Prelude Cap Mngmt Ltd Company invested 0.1% in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Voya Mngmt Lc owns 76,119 shares. Highland Mgmt Lp has invested 0.12% of its portfolio in Amicus Therapeutics, Inc. (NASDAQ:FOLD). State Board Of Administration Of Florida Retirement Systems accumulated 0% or 78,421 shares. Citigroup Inc owns 47,567 shares. Goldman Sachs Grp Inc invested 0% in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Massachusetts Fin Communication Ma invested in 676,117 shares. Ameritas Inv Prns stated it has 12,303 shares or 0.01% of all its holdings. Aperio Group Incorporated Lc holds 0% in Amicus Therapeutics, Inc. (NASDAQ:FOLD) or 15,326 shares. 5.99M are owned by Morgan Stanley. 60,900 are owned by Art Advsrs Limited. Wells Fargo & Mn has 0% invested in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Deutsche Savings Bank Ag invested 0.02% in Amicus Therapeutics, Inc. (NASDAQ:FOLD).

Among 9 analysts covering Amicus Therapeutics (NASDAQ:FOLD), 8 have Buy rating, 0 Sell and 1 Hold. Therefore 89% are positive. Amicus Therapeutics had 22 analyst reports since August 18, 2015 according to SRatingsIntel. Leerink Swann maintained Amicus Therapeutics, Inc. (NASDAQ:FOLD) rating on Monday, October 5. Leerink Swann has “Outperform” rating and $21 target. The rating was maintained by Cowen & Co on Sunday, June 25 with “Buy”. The rating was maintained by JP Morgan with “Overweight” on Tuesday, September 8. Cowen & Co maintained the stock with “Buy” rating in Tuesday, September 1 report. The stock has “Buy” rating by Leerink Swann on Monday, August 31. Bank of America initiated Amicus Therapeutics, Inc. (NASDAQ:FOLD) on Wednesday, May 18 with “Buy” rating. The stock of Amicus Therapeutics, Inc. (NASDAQ:FOLD) has “Buy” rating given on Tuesday, March 8 by Janney Capital. Robert W. Baird maintained it with “Outperform” rating and $15 target in Wednesday, July 12 report. The firm has “Neutral” rating by Goldman Sachs given on Wednesday, March 30. The rating was maintained by Leerink Swann with “Outperform” on Thursday, February 8.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: